A comprehensive view of Capsules/Pills/Tablets. This page highlights a small sample of our full coverage.
For real-time access, please log in to your R&D/Patents Market Intelligence Service.
Recent Articles
sample of recent headlines, press releases and get more..
Raymond James: Perrigo's acquisition of HRA Pharma may be overlooked by investors, as HRA is expected to file application for OTC birth control pill by end-2022; in light of Roe v. Wade ruling, potential annual sales of HRA pill could hit US$100M-US$200M
Published:
June 27, 2022
by Benzinga Lightning Feed
|
FDA grants accelerated approval for oral Tafinlar dabrafenib and Mekinist trametinib from Novartis to treat unresectable or metastatic solid tumors with BRAF V600E mutation in adult, pediatric patients; BRAF V600E accounts for 90% of BRAF-mutant cancers
Published:
June 27, 2022
by PharmaBiz
|
Bristol Myers Squibb reports Phase 3 trials show early Zeposia ozanimod oral treatment improved or preserved cognitive function in patients with relapsing multiple sclerosis; MS affects 700,000 people in Europe, 2.5 million people globally
Published:
June 27, 2022
by Business Wire
|
Analysts on Enanta suing Pfizer over Covid pill Paxlovid: SVB Securities says it's unclear whether Enanta is in the right, noting patent dates might not prove who 'invented' technology first; RBC says it could take years for lawsuit to reach conclusion
Published:
June 22, 2022
by Investor's Business Daily
|
Enanta files suit in US District Court against Pfizer seeking damages for copyright infringement related to Paxlovid nirmatrelvir, ritonavir tablets; Enanta applied for a patent for a coronavirus protease inhibitor in 2020 and received patent this month
Published:
June 22, 2022
by Business Wire
|
Ask us about our R&D/Patents market view
Trending Chart
Interactive chart with headline count